30 Week Study of the Combination of ABT-335 and Rosuvastatin Compared to Rosuvastatin Monotherapy for Subjects With Dyslipidemia and Stage 3 Chronic Kidney Disease

• Status: Completed
• Trial end date: 2011-04-01

Summary

The objective of this study is to evaluate the safety and efficacy of the combination of ABT-335 plus rosuvastatin in dyslipidemic subjects with Chronic Kidney Disease (CKD) Stage 3.

• Phase: Phase 3

Details

• Lead Sponsor: AstraZeneca
• Treatments: Fenofibric acid; Rosuvastatin Calcium